Generer rapport
Symphogen A/S
Pederstrupvej 93, 2750 Ballerup, CVR 10013267
Virksomhedsform
Aktieselskab
Etableret
2000
Størrelse
Mellemstore
Ansatte
144
Omsætning
471
MDKK
Bruttofortj.
206
MDKK
Primært resultat (EBIT)
39
MDKK
Årets resultat
49
MDKK
Egenkapital
186
MDKK
annonce
Flere nøgletal og analyser?
Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!
Rang Årets resultat
Rang i branche
10/972
"Top 10%"
Rang i Danmark
3.108/343.294
"Top 10%"
Direktion top 3
Bestyrelse top 3
| Claude Philippe Bertrand 1 | Bestyrelsesformand |
| Benoit Alain Antoine Chéron 1 | Bestyrelsesmedlem |
| Christophe Jacques Alain Henri Thurieau 1 | Bestyrelsesmedlem |
Legale ejere top 3
| 100% | Les Laboratoires Servier | FR |
Tegningsregler
Selskabet tegnes af to medlemmer af bestyrelsen i forening eller af et bestyrelsesmedlem i forening med en direktør eller af den administrerende direktør.
Stamoplysninger baseret på CVR
| Navn | Symphogen A/S |
| CVR | 10013267 |
| Adresse | Pederstrupvej 93, 2750 Ballerup |
| Branche | Forskning og eksperimentel udvikling indenfor bioteknologi [721100] |
| Etableret | 01-01-2000 (24 år) |
| Første regnskabsperiode | 01-01-2000 til 31-12-2000 |
| Virksomhedsform | Aktieselskab |
| Antal ansatte | 179 (årsværk:156) |
| Reklamebeskyttelse | Nej |
| Revisor | Ey Godkendt Revisionspartnerselskab siden 10-10-2014 |
| Regnskabsperiode | 01-10 til 30-09 |
| Selskabskapital | 11.292.369 DKK 3.587.521 DKK (20-06-2019 - 02-06-2020) 1.808.324 DKK (29-05-2019 - 19-06-2019) 15.403.759 DKK (20-06-2018 - 28-05-2019) 15.403.609 DKK (29-01-2018 - 19-06-2018) 15.216.625 DKK (25-09-2017 - 28-01-2018) |
| Vedtægter seneste | 15-03-2023 |
Medlem af brancherne
- Forskning og eksperimentel udvikling indenfor bioteknologiNACE6 indeholdende 555 virk.
- Forskning og eksperimentel udvikling indenfor naturvidenskab og teknikNACE3 indeholdende 1.757 virk.
- Videnskabelig forskning og udviklingNACE2 indeholdende 2.048 virk.
- Liberale, videnskabelige og tekniske tjenesteydelserNACE1 indeholdende 86.700 virk.
Formål
Selskabets formål er at forske, udvikle, producere og sælge, herunder gennem ind- og udlicensering, produkter, processer, teknologier, service og andre beslægtede forretningsområder efter bestyrelsens skøn.
Regnskab
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Valuta/enhed | 000' DKK | 000' DKK | 000' DKK |
| Omsætning | 471.468 +573% | 70.019 -85% | 458.964 - |
| Bruttofortjeneste | 205.932 - | - - | - - |
| Årets resultat | 49.113 -70% | 165.734 +91% | 86.877 - |
| Egenkapital | 186.388 +36% | 137.275 - | -28.459 - |
| Balance | 368.202 +21% | 303.252 +6% | 285.011 - |
Ledelsesberetning
Revenue increased from DKK 70 million in 2021/2022 to DKK 471 million in 2022/2023.
In 2021/2022 were Other operating income reported of DKK 533 million, related to income from sale of IP rights. No other operating income was reported in 2022/2023.
Net result for the year ended 30th September 2023, amounted to a profit of DKK 49 million compared to profit of DKK 166 million for the year ended 30th September 2022.
On 30th September 2023, total equity amounted DKK 186 million and total assets amounted DKK 368 million.
Development in 2022/2023 compared to prior years expressed expectations
In the financial statement for 2021/22 our outlook for 2022/23 expressed expected revenue for 2022/2023 within the range of DKK 600-700 million and net result within the range of DKK 0-110 million. Actual revenue and net result for 2022/23 deviated from those expressed expectations, primarily to close down of certain R&D projects and as a result reduction in activity level of service activities rendered under the reseach and collaboration agreement with Servier.
Investments
Investments amounted to DKK 38 million in 2022/2023 against DKK 18 million in 2021/2022. The increase, of which DKK 11 million related to rigth of use lease assets, was mainly driven by investments in laboratory equipment and capacities.
Change in financial reporting framework from IFRS to the Danish Financial Statements Act
In previous years and through 30 September 2022, the Company prepared and presented its financial statements in accordance with International Reporting Standards (IFRS) as adopted by the EU. Due to a change in the nature and direction of the business, the Company has elected to change its accounting framework and prepare and present the financial statements for 2022/23 in accordance with the Danish Financial Statements Act.
Refer to note 1 for further details and description of the change in accounting policies.
Change in share capital
At September 30, 2022, the share capital consisted of DKK 0 class D shares (common shares), DKK 7,434,726 class J shares (preferred shares) and DKK 3,857,643 class L shares (preferred shares). Class J shares and class L shares were convertible into common shares in certain situations and subject to certain terms and conditions.
In March 2023, the Company changed its share capital structure and closed and merged the share classes D, J, L into one single share class. Following the change and on September 30, 2023, Symphogen's share capital amounts to DKK 11,292,369 divided into shares of DKK 1.
In 2021/2022 were Other operating income reported of DKK 533 million, related to income from sale of IP rights. No other operating income was reported in 2022/2023.
Net result for the year ended 30th September 2023, amounted to a profit of DKK 49 million compared to profit of DKK 166 million for the year ended 30th September 2022.
On 30th September 2023, total equity amounted DKK 186 million and total assets amounted DKK 368 million.
Development in 2022/2023 compared to prior years expressed expectations
In the financial statement for 2021/22 our outlook for 2022/23 expressed expected revenue for 2022/2023 within the range of DKK 600-700 million and net result within the range of DKK 0-110 million. Actual revenue and net result for 2022/23 deviated from those expressed expectations, primarily to close down of certain R&D projects and as a result reduction in activity level of service activities rendered under the reseach and collaboration agreement with Servier.
Investments
Investments amounted to DKK 38 million in 2022/2023 against DKK 18 million in 2021/2022. The increase, of which DKK 11 million related to rigth of use lease assets, was mainly driven by investments in laboratory equipment and capacities.
Change in financial reporting framework from IFRS to the Danish Financial Statements Act
In previous years and through 30 September 2022, the Company prepared and presented its financial statements in accordance with International Reporting Standards (IFRS) as adopted by the EU. Due to a change in the nature and direction of the business, the Company has elected to change its accounting framework and prepare and present the financial statements for 2022/23 in accordance with the Danish Financial Statements Act.
Refer to note 1 for further details and description of the change in accounting policies.
Change in share capital
At September 30, 2022, the share capital consisted of DKK 0 class D shares (common shares), DKK 7,434,726 class J shares (preferred shares) and DKK 3,857,643 class L shares (preferred shares). Class J shares and class L shares were convertible into common shares in certain situations and subject to certain terms and conditions.
In March 2023, the Company changed its share capital structure and closed and merged the share classes D, J, L into one single share class. Following the change and on September 30, 2023, Symphogen's share capital amounts to DKK 11,292,369 divided into shares of DKK 1.
15-02-2024